We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Study cycle definition

Study cycle. Second cycle Subject area: [degree in sending institution] Code: [ISCED-F code] Number of completed higher education study years: Student with: a financial support from EU funds  a zero-grant from EU funds 
Study cycle refers to either bachelor or master and will thus provide these options in the relevant dropdown-menu. • It is particularly tricky to complete theField of education” box. Entering the normal programme title will not work. Please use the title as provided in the list you can find here: xxxxx://xxx.xx- xxxxxxxxxx.xx/xxxxxxxxx/xxxx_xxxxxx/xx_xx/Xxxxxxxxx/Xxxxxxx_XXXXX- Codes_Field_of_Education_Zuordnung_zu_den_Fakultaeten.pdf
Study cycle. [First cycle/ Second cycle/ Third cycle / Short cycle / One-cycle study programme] Subject area: [field of study in sending institution] Code: [ISCED-F code] Study year: The financial support includes: special needs support exceptional needs to support participants with fewer opportunities Bank account the financial support should be paid to: Account number: Account holder (if different than student) Bank name BIC/SWIFT IBAN Currency of the bank account hereafter referred to as “the participant”, of the other part, have agreed the Special conditions and Annexes below which form an integral part of this agreement (“the agreement”): Annex I Learning Agreement for Studies / Learning Agreement for Traineeship / Learning Agreement for Studies and Traineeship Xxxxx XX Certificate of Attendance Xxxxx XXX General Conditions The terms set out in the Special conditions shall take precedence over those set out in the annexes.

Examples of Study cycle in a sentence

  • Study cycle: Short cycle (EQF level 5) / Bachelor or equivalent first cycle (EQF level 6) / Master or equivalent second cycle (EQF level 7) / Doctorate or equivalent third cycle (EQF level 8).

  • The ISO shall prioritize and list the sensitivities that can be completed during the Economic Study cycle taking into consideration the impact of the additional efforts on the ISO resources and other priorities.

  • If the Economic Study cycle and potential resulting competitive request for proposals process cannot be completed within the initial schedule, the ISO shall notify stakeholders of such, provide a revised estimated completion date, and provide an explanation of the reason or reasons why the additional time is required.

  • Given these contrasting results, the investment function we introduce in section 3.1 presents an opportunity to test the robustness of the financialisation thesis, at least since the mid-nineties, which is close to the period taken by Hecht (2014).

  • The ISO shall provide to the Planning Advisory Committee the schedule for the Economic Study cycle within three months of initiating the process.

  • Mr. Rosario testified that the Knox County Solar Project is in the 2019 MISO DPP Study cycle and is slated for commercial operation no later than December 31, 2023.

  • Study cycle Short cycle (EQF level 5) / Bachelor or equivalent first cycle (EQF level 6) / Master or equivalent second cycle (EQF level 7) / Doctorate or equivalent third cycle (EQF level 8).

  • SPP notes that, if interconnection customers that are not ready to build their generation facilities and network upgrades are allowed to move to the Interconnection Facility Study Queue, the stand-alone scenario will provide no value because a restudy will be required for every Interconnection Facilities Study cycle to determine the upgrades required for the interconnection customers that move forward.

  • They offer training courses for LS facilitators and organize LS conferences and publish in professional and scientific journals about their LS approach.The Dutch Lesson Study cycle starts with an orientation on the theme and determining the goal through, for example, literature study, inventory of good practices, exploration of the practical theory of participating teachers or of expert teachers.

  • I combined this with my understanding of Fernandez & Yoshida’s (2004) overview of a Lesson Study cycle in Japan and felt that it would be important to my own understanding to explore both the expertise and the collaboration needed within Lesson Study cycles.


More Definitions of Study cycle

Study cycle. [First/Second/Third] Subject area/degree in sending institution: Code: [ISCED-F code, click below] Number of completed higher education study years: ☐ 0313 Applied Psychology ☐ 0210 Art Education, Audiovisual Media Culture, Applied Visual Arts ☐ 0212 Design (Clothing, Graphic, Interior and Textile, Industrial, Service) ☐ 0110 Education ☐ 0421 Law ☐ 0413 Management and Administration ☐ 0312 Political Sciences ☐ 0923 Social Work ☐ 0314 Sociology ☐ 0113 Teacher Training without subject specialisation ☐ 1015 Tourism Research Student with: ☐ A financial support from Erasmus+ EU funds ☐ A zero-grant ☐ A financial support from Erasmus+ EU funds combined with zero-grant The financial support includes: ☐ Special needs support ☐ Financial support to student with children Called hereafter “the participant”, of the other part, Have agreed to the Special Conditions below and Annexes in SoleMOVE mobility system, which form an integral part of this agreement ("the agreement"): Annex I Learning Agreement for Traineeship Xxxxx XX General Conditions Xxxxx XXX Xxxxxxx Student Charter
Study cycle. Bachelor or equivalent first cycle (EQF level 6) / Master or equivalent second cycle (EQF level 7) / Doctorate or equivalent third cycle (EQF level 8). To note: at Imperial College the final year of the MEng or MSci degree would equate to Master.
Study cycle. ☐First cycle ☐Second cycle ☐Third cycle ☐Short cycle ☐One-cycle study programme Home Faculty/School: Name of diploma registered in current academic year in home institution: Title of CIVIS project: Host Institution name: Location of physical mobility (address) Bank account where the financial support should be paid: Bank account holder (if different than student): Bank name: BIC/SWIFT : IBAN : Have agreed to the Conditions and Annex(es) below which form an integral part of this agreement ("the agreement"): ☐ Annex I: Physical activities’ programme
Study cycle. ☐First cycle ☐Second cycle ☐Third cycle ☐Short cycle ☐One-cycle study programme Cycle d’études : ☐1er cycle ☐2è cycle ☐3è cycle ☐cycle court ☐cycle unique Subject area (degree in sending institution): Domaine d’études (diplôme de l’établissement d’envoi) : ISCED- F Code / Code CITE-F : Number of completed higher education study years: Nombre d’années d’études supérieures achevées : Student with / Le participant sera : ☐ a financial support from Erasmus+ EU funds / allocataire de fonds européens Erasmus+ ☐ a zero-grant / non-allocataire de fonds européens Erasmus+ ☐ a financial support from Erasmus+ EU funds combined with zero-grant / partiellement allocataire de fonds européens Erasmus+. The financial support includes / L’aide financière comprendra : ☐ special needs support / un complément de financement en raison d’une situation de handicap. For all participants receiving financial support from Erasmus+ EU funds, except those receiving ONLY a zero-grant from EU funds: Informations bancaires à compléter pour les participants recevant une aide financière Erasmus+ (ne concerne pas les non-allocataires) : Bank account where the financial support should be paid: Numéro de compte bancaire sur lequel la subvention sera versée : Bank account holder (if different than student): Titulaire du compte (si différent de l’étudiant) : Bank name: Nom de la banque : BIC/SWIFT : IBAN : Have agreed to the Special Conditions and Annexes below which form an integral part of this agreement ("the agreement"): ont accepté les conditions particulières et annexes ci-dessous, qui font partie intégrante du présent contrat (« le contrat ») : Annex I ☐ Learning Agreement for Erasmus+ mobility for studies / Contrat pédagogique pour les mobilités d’études Annex II ☐ General Conditions / Conditions générales Annex IIIErasmus Student Charter / Charte de l’étudiant Erasmus+. The terms set out in the Special Conditions shall take precedence over those set out in the annexes. It is not compulsory to circulate papers with original signatures for Annex I of this document: scanned copies of signatures and electronic signatures may be accepted, depending on the national legislation or institutional regulations. Les conditions particulières prévalent sur les annexes. L’annexe I ne devra pas obligatoirement comporter les signatures originales, les signatures scannées et électroniques étant acceptées, selon la législation nationale en vigueur.
Study cycle. [First cycle/Second cycle/Third cycle/long-cycle] Subject area: [degree in sending institution] Code: [ISCED-F code] Number of completed higher education study years: Student with: a financial support from EU funds  a zero-grant from EU funds  a financial support from EU funds for [xxx] days combined with zero-grant from EU funds for [xxx] days  The financial support includes: Special needs support  Financial Support to student having rights to receive a merit-based stipend as defined in the HEI’s internal regulations  [For all participants receiving financial support from EU funds, except those receiving ONLY a zero-grant from EU funds]. Bank account where the financial support should be paid: Bank account holder (if different than student): Bank name: Clearing/BIC/SWIFT number: Account/IBAN number: called hereafter “the participant” of the other part, have agreed the Special Conditions and Annexes below which form an integral part of this agreement ("the agreement"): Annex I [Institution to select: Learning Agreement for Erasmus+ mobility for studies/ Learning Agreement for Erasmus+ mobility for traineeships/Learning Agreement for Erasmus+ mobility for studies and for traineeships] Annex II General Conditions Annex III Erasmus Student Charter [It is not compulsory to circulate papers with original signatures for Annex I of this document: scanned copies of signatures and electronic signatures may be accepted, depending on the national legislation.]
Study cycle choose your study cycle (at DTU) at the time of the exchange STEP 2: Sending institution: • Choose Denmark and then DTU via the two drop down menus.

Related to Study cycle

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase I Study means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Phase 1 Clinical Trial means a human clinical trial of a Licensed Product that would satisfy the requirements of 21 C.F.R. 312.21(a) or corresponding foreign regulations.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Study Period means the period commencing at 9:00 a.m. on the date hereof, and continuing through 5:00 p.m. on the Closing Date.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase II Study means a study in humans of the safety, dose ranging or efficacy of a product, as further defined in 21 C.F.R. § 312.21(b) (or the equivalent thereof outside the United States).

  • Clinical Study means a Xxxxx 0 Xxxxx, Xxxxx 2 Study, Phase 3 Study, Post-Marketing Study, Supplemental Study or other study (including a non-interventional study) in humans to obtain information regarding the product, including information relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product.

  • Phase 2 Trial means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. §312.21(b) (including any such clinical study in any country other than the United States).

  • Feasibility Study means the evaluation and analysis of the potential of a project, which aims at supporting the process of decision-making by objectively and rationally uncovering its strengths and weaknesses, opportunities and threats, as well as identifying the resources required to carry it through and ultimately its prospects for success;

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase II Clinical Trial means a study in humans of the safety, dose ranging and efficacy of a product, which is prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial or to file for accelerated approval, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(b) or its foreign equivalents.

  • Pivotal Study means (a) a Phase 3 Study that is intended by Celgene to be submitted (together with any other registration trials that are prospectively planned when such Phase 3 Study is initiated) for Regulatory Approval in the U.S. or the EU, or (b) any other clinical study that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which clinical study is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for the Licensed Product in the U.S. or another country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such study.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Clinical Trial means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval human clinical trial, as applicable.

  • Phase 3 Study means a clinical study of a drug candidate in human patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.

  • Phase III Clinical Trial means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.

  • Phase II Trial means a clinical trial of a Licensed Product, designated as a Phase II Trial and the principal purpose of which is to make a preliminary determination that such Licensed Product is safe and active in a patient population for its intended use and is designed to obtain sufficient information about such Licensed Product’s efficacy to permit the design of a Phase III Trial(s), and generally consistent with 21 CFR § 312.21(b). For purposes of this definition, Phase II trial shall specifically exclude expansion cohorts from Phase I Trial(s).

  • Phase I Trial means a clinical trial of a Licensed Product in human patients designated as a Phase I Trial and conducted primarily for the purpose of determining the safety of and/or the metabolism and pharmacologic actions of the Licensed Product in humans, as described under 21 CFR § 312.21(a) (as hereafter modified or amended) and any of its foreign equivalents. For purposes of this definition, Phase I Trial shall specifically exclude trials in healthy volunteers.